Biomarkers VWF and ADAMTS13 and use thereof in liver cirrhosis diagnostic reagents

Abstract

Relating to the field of use of disease biomarkers, the invention discloses liver cirrhosis biomarkers VWF (von willebrand factor) and ADAMTS13 (adisintegrin and metalloproteinase with thrombospondin motifs 13) and use thereof in liver cirrhosis diagnostic reagents. The VWF is composed of protein with an amino acid sequence accession number of GI 317373549 in a NCBI database, and the ADAMTS13 is composed of protein with an amino acid sequence accession number of GI 74749836 in a NCBI database. Use of the biomarkers VWF and ADAMTS13 for liver cirrhosis diagnosis on subjects has the advantages of simplicity and feasibility, safe and non-invasive diagnostic process and easy acceptance by patients, unified diagnosis standard insusceptible to subjective factors, high diagnosis result specificity and sensitivity, and easy mass screening and selection, etc.

Description

technical field

[0001] The invention relates to the field of application of disease biomarkers, in particular to liver cirrhosis biomarkers VWF and ADAMTS13 and their use in liver cirrhosis diagnostic reagents. Background technique

[0002] Liver cirrhosis is a chronic progressive liver disease with diffuse liver damage caused by long-term or repeated effects of one or more causes. In my country, most of them are post-hepatitis cirrhosis, and a small part are alcoholic cirrhosis and schistosome cirrhosis. Histopathologically, extensive liver cell necrosis, nodular regeneration of residual liver cells, connective tissue hyperplasia, and fibrous septum formation lead to structural destruction of hepatic lobules and formation of pseudolobules. The liver gradually deforms and hardens and develops into cirrhosis. In the early stage, there are no obvious symptoms due to the strong compensatory function of the liver. In the later stage, liver function damage and portal hypertensio...

Images